Cancer Family
Lymphocytic Neoplasm
CI-CAN-00000223Explore in graph →
HematologicNon-malignant3,037 active trials72 approved drugs345 evidence items
- NCIt
- C7065
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000223Explore in graph →
Clinical trials
12,948 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05673447 | The Study of Anti-CD19 CAR NK Cells in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma | unknown | Early Phase 1 | 12 | Changhai HospitalOTHER | 1 | Aug 28, 2023 | clinicaltrials |
| NCT05979792 | Clinical Study of CD7 CAR-T Cell Injection in the Treatment of Patients With Relapsed or Refractory CD7-positive Peripheral T Cell Lymphoma | unknown | Early Phase 1 | 35 | Zhao WeiliOTHER | 1 | Aug 21, 2023 | clinicaltrials |
| NCT03591614 | Dendritic Cell DKK1 Vaccine for Monoclonal Gammopathy and Stable or Smoldering Myeloma | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT03219047 | Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma | completed | Early Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 27, 2023 | clinicaltrials |
| NCT05715606 | Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research | unknown | Early Phase 1 | 18 | Anhui Provincial HospitalOTHER_GOV | 1 | Jul 5, 2023 | clinicaltrials |
| NCT03272633 | Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies | terminated | Early Phase 1 | 2 | Rutgers, The State University of New JerseyOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT02640209 | Pilot Trial Of Autologous T Cells Engineered To Express Anti-CD19 Chimeric Antigen Receptor (CART19)In Combination With Ibrutinib In Patients With Relapsed Or Refractory CD19+ Chronic Lymphocytic Leukemia (CLL)Or Small Lymphocytic Lymphoma (SLL) | terminated | Early Phase 1 | 20 | University of PennsylvaniaOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03371420 | PET Imaging of Subjects Using 124I-PU-AD | terminated | Early Phase 1 | 5 | Samus Therapeutics, Inc.INDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05739227 | Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies | unknown | Early Phase 1 | 12 | Xuzhou Medical UniversityOTHER | 1 | Feb 22, 2023 | clinicaltrials |
| NCT03281811 | Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides | completed | Early Phase 1 | 11 | Mayo ClinicOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05655676 | 89Zr-labeled NY008 PET Imaging in Patients | unknown | Early Phase 1 | 10 | Affiliated Hospital of Jiangnan UniversityOTHER | 1 | Dec 19, 2022 | clinicaltrials |
| NCT05652530 | Clinical Study of the Safety and Efficacy of BCMA CAR-NK | unknown | Early Phase 1 | 19 | Shenzhen Pregene Biopharma Co., Ltd.INDUSTRY | 1 | Dec 15, 2022 | clinicaltrials |
| NCT05651191 | To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL | unknown | Early Phase 1 | 9 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 14, 2022 | clinicaltrials |
| NCT04860817 | A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05015972 | UCAR-T for CD19+ Refractory/Relapsed B Hematologic Malignancies | withdrawn | Early Phase 1 | 0 | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of ChinaOTHER | 1 | Nov 29, 2022 | clinicaltrials |
| NCT04984330 | Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory Disease(STARR) | withdrawn | Early Phase 1 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT02851056 | Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT) | completed | Early Phase 1 | 14 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05271279 | A Study of OVV-01 Injection in Combination With IBR900 Cell Injection in Patients With Advanced Malignant Tumors | terminated | Early Phase 1 | 2 | Beijing Boren HospitalOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05016778 | A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma | unknown | Early Phase 1 | 15 | Zhejiang UniversityOTHER | 1 | Nov 1, 2022 | clinicaltrials |
| NCT02405078 | Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | completed | Early Phase 1 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05013372 | CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma | unknown | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT05478343 | Clinical Trial to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Multiple Myeloma | unknown | Early Phase 1 | 10 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 28, 2022 | clinicaltrials |
| NCT05444322 | A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | unknown | Early Phase 1 | 18 | He HuangOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT05430945 | A Study of BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 100 | Zhejiang UniversityOTHER | 1 | Jun 24, 2022 | clinicaltrials |
| NCT02046694 | A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL | completed | Early Phase 1 | 34 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04657861 | APRIL CAR-T Cell Therapy for Patients With BCMA/TACI Positive Relapsed and/or Refractory Multiple Myeloma | recruiting | Early Phase 1 | 36 | Zhejiang UniversityOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05364177 | 68Ga-pentixather and 68Ga-pentixafor PET/CT in Multiple Myeloma | unknown | Early Phase 1 | 100 | Peking Union Medical College HospitalOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03825718 | A Study of GC007F CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL | completed | Early Phase 1 | 29 | Hebei Yanda Ludaopei HospitalOTHER | 1 | Apr 28, 2022 | clinicaltrials |
| NCT05239676 | Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma | unknown | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT04697290 | CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. | suspended | Early Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05008536 | Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma | unknown | Early Phase 1 | 27 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
| NCT03585725 | A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma | terminated | Early Phase 1 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT04617704 | BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT00424242 | Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases | completed | Early Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03943472 | BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma | unknown | Early Phase 1 | 10 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Aug 31, 2021 | clinicaltrials |
| NCT04264078 | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | unknown | Early Phase 1 | 30 | Xinqiao Hospital of ChongqingOTHER | 1 | Jun 28, 2021 | clinicaltrials |
| NCT04236011 | BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma | unknown | Early Phase 1 | 15 | Shanghai Changzheng HospitalOTHER | 1 | Jun 15, 2021 | clinicaltrials |
| NCT04767308 | Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies | unknown | Early Phase 1 | 18 | Huazhong University of Science and TechnologyOTHER | 0 | Feb 23, 2021 | clinicaltrials |
| NCT04696705 | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | unknown | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04227015 | A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy | recruiting | Early Phase 1 | 72 | He HuangOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT04670055 | A Study of Humanized BCMA-targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 17, 2020 | clinicaltrials |
| NCT04541368 | A Study of CS1-targeted CAR-T Cells Therapy for Relapsed Multiple Myeloma After BCMA CAR-T Cells Therapy | not yet recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Dec 10, 2020 | clinicaltrials |
| NCT02181478 | Intra-Osseous Co-Transplant of UCB and hMSC | completed | Early Phase 1 | 6 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04650724 | Clinical Study of T Cell Infusion Targeting BCMA Chimeric Antigen Receptor | completed | Early Phase 1 | 3 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04638270 | Anti-CD19 FasT CAR-T Cell Therapy for B Cell NHL | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04639739 | Anti-CD19 CAR NK Cell Therapy for R/R Non-Hodgkin Lymphoma. | unknown | Early Phase 1 | 9 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04637269 | Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma | unknown | Early Phase 1 | 16 | Xinqiao Hospital of ChongqingOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT04626726 | Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation | unknown | Early Phase 1 | 50 | Hebei Senlang Biotechnology Inc., Ltd.INDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 28, 2023source: clinicaltrials